Boston Partners Has $4.38 Million Holdings in Trinity Biotech (TRIB)

Boston Partners trimmed its holdings in shares of Trinity Biotech (NASDAQ:TRIB) by 20.8% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 851,130 shares of the company’s stock after selling 223,090 shares during the period. Boston Partners owned about 3.54% of Trinity Biotech worth $4,383,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Lapides Asset Management LLC boosted its holdings in shares of Trinity Biotech by 3.3% during the first quarter. Lapides Asset Management LLC now owns 1,211,900 shares of the company’s stock worth $6,241,000 after purchasing an additional 38,500 shares during the period. Deutsche Bank AG boosted its holdings in shares of Trinity Biotech by 3,969,200.0% during the fourth quarter. Deutsche Bank AG now owns 39,693 shares of the company’s stock worth $202,000 after purchasing an additional 39,692 shares during the period. Millennium Management LLC boosted its holdings in shares of Trinity Biotech by 20.8% during the fourth quarter. Millennium Management LLC now owns 403,587 shares of the company’s stock worth $2,058,000 after purchasing an additional 69,469 shares during the period. Hunter Associates Investment Management LLC boosted its holdings in shares of Trinity Biotech by 10.9% during the fourth quarter. Hunter Associates Investment Management LLC now owns 711,185 shares of the company’s stock worth $3,627,000 after purchasing an additional 70,174 shares during the period. Finally, Adirondack Research & Management Inc. boosted its holdings in shares of Trinity Biotech by 22.2% during the fourth quarter. Adirondack Research & Management Inc. now owns 408,337 shares of the company’s stock worth $2,083,000 after purchasing an additional 74,162 shares during the period. Institutional investors and hedge funds own 70.35% of the company’s stock.

Trinity Biotech opened at $4.48 on Friday, MarketBeat reports. The company has a quick ratio of 3.49, a current ratio of 5.03 and a debt-to-equity ratio of 1.45. The stock has a market cap of $95.23 million, a PE ratio of 17.23 and a beta of 1.34. Trinity Biotech has a 1-year low of $4.46 and a 1-year high of $4.46.

Trinity Biotech (NASDAQ:TRIB) last issued its quarterly earnings data on Tuesday, May 1st. The company reported $0.02 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.05 by ($0.03). Trinity Biotech had a positive return on equity of 3.26% and a negative net margin of 41.38%. The company had revenue of $23.80 million during the quarter.

A number of analysts have recently weighed in on the stock. ValuEngine lowered shares of Trinity Biotech from a “sell” rating to a “strong sell” rating in a report on Saturday, April 21st. Zacks Investment Research lowered shares of Trinity Biotech from a “hold” rating to a “sell” rating in a report on Friday, April 13th.

About Trinity Biotech

Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease, sexually transmitted diseases, respiratory infections, epstein barr virus, and other viral pathogens; and products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a high risk of developing diabetes.

Institutional Ownership by Quarter for Trinity Biotech (NASDAQ:TRIB)

Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.



Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit